Avesthagen, the Bangalore-based life sciences firm, is understood to be finalising a joint venture at one its four strategic business units (SBU). The joint venture partner from overseas is expected to be announced during next week to develop one of the product lines under a SBU.

Avesthagen has four strategic business units - biopharmaceuticals, bionutrition, bioagriculture and science and innovation and is hoping to touch a topline of Rs 100 crore by end of the fiscal.

Click here for Cloud Computing

Also Read   Related Stories News Now - MindTree restructures trainee salaries, to be paid in tranches - Avesthagen ties up with Chilean biotech firm

Also Read   Related Stories News Now - Wall Street opens flat as data offsets Moody's warning - Govt to talk to all parties for consensus on Lok Pal - Kingfisher needs more funds to remain going concern: auditors - We don't want player retention policy in future IPL: Roy - ONGC may invoke force majeure clause for 2 KG blocks More

Avesthagen is an integrated systems biology platform company that focuses on the convergence of food, pharma and population genetics leading to predictive, preventive, personalized healthcare. Avesthagen employs 650 plus people and continues to build integrated, systems biology approach of capabilities, infrastructure and technology that allows for and facilitates ‘cross talk’ between numerous disciplines, leading to solutions.

The business model of the company is to combine IP and product development for long term sustainable revenue generation and value addition, with R and D services and collaborative research programs forôwith other parties to generate revenue stream and market focus.

The promoters hold 32 per cent while a clutch of external investors ranging from the Tata Group, Godrej, Danone, ICICI Venture, Cipla, funds from Fidelity, Groupe Limagrin and New York Life Management India Fund are investors in the company and various of its product lines. Avesthagen recently announced that it intends to revive its IPO plans during next year. According to Avesthagen, the IPO proceeds will be used to commercialise 40 products which are in various stages of development.

, to market. The IPO is slated to coincide with the time that its biosimilars are ready to hit the marketplace.

New Ipad Application :Business Standard's all new IPad App Click here to download for free Other Stories      - Wall Street opens flat as data offsets Moody's warning - Govt to talk to all parties for consensus on Lok Pal - Kingfisher needs more funds to remain going concern: auditors - We don't want player retention policy in future IPL: Roy - ONGC may invoke force majeure clause for 2 KG blocks

Tags : Avesthagen | strategic business units   Read Business news in  Advertisements -  Now property search gets more exciting than ever before! -  High Growth Business Opportunities in Africa - Register to explore -  Medium-sized businesses are the engines of a smarter planet. -  Save over Rs.3000 with IndianOil Citibank Card -  We live for our family. have you secured them? -  India's No. 1 Property Site. Click here to know more.. -  Diseases earlier, Saving Costs, Extending Lives. Know More.. -  Get 5% cashback on telephone bills with Citi -  Enjoy the journey as much as the destination. click to know more.. -  Exim Bank Conclave on India - Africa Project Partnership. Know more.. -  Be part of it The World's Largest Aircraft. -  Creating Wealth made simple the SIP way. Know more.. -  Only Developer to give a guarantee on time space & rate. -  Office 365 for professionals and small businesses. -  Buy Your Property with Our Triple Guarantee in India. -  Improve Patient Care & Experience. Click here to know more -  Win a Business Class Ticket to Europe..Know more.. -   Introduce a New Automotive Luxury Car.. know more -  Health is Wealth..... Insurance + Savings... Know More...